Antitumor effect research progress of shikonin and its derivatives

Yaoxue Xuebao

Volumn 47, Issue 5, 2012, Pages 588-593

  Zhu, Meng Yuan ^a   Wang, Ru Bing ^a   Zhou, Wen ^a   Li, Shao Shun ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Anti tumor effect; Antiangiogenesis; Apoptosis; Matrix metalloproteinase; Necrosis; Protein tyrosine kinase; Shikonin

Indexed keywords

MATRIX METALLOPROTEINASE; PROTEIN TYROSINE KINASE; SHIKONIN DERIVATIVE;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CELL DEATH; LITHOSPERMUM; NONHUMAN; REVIEW;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CELL LINE, TUMOR; DRUGS, CHINESE HERBAL; HUMANS; LITHOSPERMUM; MATRIX METALLOPROTEINASE 9; NAPHTHOQUINONES; NECROSIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PLANTS, MEDICINAL; PROTEIN-TYROSINE KINASES; REACTIVE OXYGEN SPECIES;

EID: 84863689064     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Zhou W, Jiang Had G, Peng Y, et al. Comparative study on enantiomeric excess of main akannin/shikonin derivatives isolated from the roots of three endemic Boraginaceae plants in China[J]. Biomed Chromatogr, 2011, 25: 1076-1075.
2. Chinese Pharmacopoeia Committee. Pharmacopoeia of People's Republic of China [S]. Part 1. Beijing: China Medical Science Press, 2010: Appendix 320.
3. Ciciarello M, Mangiacasale R, Casenghi M, et al. p53 displacement from centrosomes and p53-mediated G1 arrest following transient inhibition of the mitotic spindle [J]. J Biol Chem, 2001, 276: 19205-19213.
4. Allen JD, Schinkel AH. Multidrug resistance and pharmacological protection mediated by the breast cancer resistance protein (BCRP/ABCG2) [J]. Mol Cancer Ther, 2002, 1: 427-434.
5. Juranka P, Zastawny R, Ling V. P-glycoprotein: multidrug-resistance and a superfamily of membrane-associated transport proteins [J]. FASEB J, 1989, 3: 2583-2592. (Pubitemid 20013272)
6. Hickman ES, Moroni MC, Helin K. The role of p53 and pRB in apoptosis and cancer [J]. Curr Opin Genet Dev, 2002, 12: 60-66.
7. Papageorgiou VP, Assimopoulou AN, Couladouros EA, et al. The chemistry and biology of alkannin, shikonin, and related naphthazarin natural products [J]. Angew Chem Int Ed, 1999, 38: 270-300. (Pubitemid 29090823)
8. Yang HJ, Zhou P, Huang HB, et al. Shikonin exerts antitumor activity via proteasome inhibition and cell death induction in vitro and in vivo [J]. Int J Cancer, 2009, 124: 2450-2459.
9. Wang WJ, Dai M, Zhu CH, et al. Synthesis and biological activity of novel shikonin analogues [J]. Bioorg Med Chem Lett, 2009, 19: 735-737.
10. Zhou W, Peng Y, Li SS. Semi-synthesis and antitumor activity of 5, 8-O-dimethyl acylshikonin derivatives [J]. Eur J Med Chem, 2010,45:6005-6011.
11. Zhou W, Zhang X, Xiao L, et al. Semi-synthesis and antitumor activity of 6-isomers of 5, 8-O-dimethyl acylshikonin derivatives [J]. Eur J Med Chem, 2011, 46: 3420-3427.
12. Wang RB, Zhou SS, Li SS, et al. Development of small molecule inhibitors on Bcl-2/Bcl-Xl [J]. Chin J Med Chem, 2011, 21: 155-164.
13. Kang MH, Reynolds CP. Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy [J]. Clin Cancer Res, 2009, 15: 1126-1132.
14. 2 cells [J]. Chin Pharmacol Bull, 2005, 21: 202-205.
15. Cohen GM. Caspases: the executioners of apoptosis [J]. Biochem J, 1997, 326: 1-16. (Pubitemid 27386911)
16. Doshi JM, Tian D, Xing C. Structure-activity relationship studies of ethyl 2-amino-6-bromo-4-(l-cyano-2-ethoxy-2-oxoethyl)-4//-chromene-3-carboxylate (HA 14-1), an antagonist for antiapoptotic Bcl-2 proteins to overcome drug resistance in cancer [J]. J Med Chem, 2006, 49: 7731-7739. (Pubitemid 46033664)
17. 2+: a control point for apoptosis [J]. Science, 2003, 300: 135-139.
18. Chipuk JE, Kuwana T, Bouchier-Hayes L, et al. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis [J]. Science, 2004, 303: 1010-1014. (Pubitemid 38209704)
19. Datar SA, Jacobs HW, de la Cruz AFA, et al. The drosophila cyclin D-Cdk4 complex promotes cellular growth [J]. EMBO J, 2000, 19: 4543-4554.
20. Modiano JF, Mayor J, Ball C, et al. CDK4 expression and activity are required for cytokine responsiveness in T cells [J]. J Immunol, 2000, 165: 6693-6702. (Pubitemid 32001131)
21. Wu Z, Wu L, Li L, et al. p53-mediated cell cycle arrest and apoptosis induced by shikonin via a caspase-9-dependent mechanism in human malignant melanoma A375-S2 cells [J]. J Pharmacol Sci, 2004, 94: 166-176. (Pubitemid 38405131)
22. Masuda Y, Shima G, Aiuchi T, et al. Involvement of tumor necrosis factor receptor-associated protein 1 (TRAPl) in apoptosis induced by β-hydroxyisovalerylshikonin [J]. J Biol Chem, 2004, 279: 42503-42515. (Pubitemid 39372134)
23. Kim SH, Kang IC, Yoon TJ, et al. Antitumor activities of a newly synthesized shikonin derivative, 2-hyim-DMNQ-S-33 [J]. Cancer Lett, 2001, 172: 171-175. (Pubitemid 32889713)
24. Masuda Y, Nishida A, Hori K, et al. β-Hydroxyisovaleryl-shikonin induces apoptosis in human leukemia cells by inhibiting the activity of a polo-like kinase 1 (PLK1) [J]. Oncogene, 2003, 22: 1012-1023. (Pubitemid 36313145)
25. Singh F, Gao D, Lebwohl MG, et al. Shikonin modulates cell proliferation by inhibiting epidermal growth factor receptor signaling in human epidermoid carcinoma cells [J]. Cancer Lett, 2003, 200: 115-121 (Pubitemid 38366091)
26. Wang RB, Zhou SS, Li SS. Cancer therapeutic agents targeting hypoxia-inducible factor-1 [J]. Curr Med Chem, 2011, 18: 3168-3189.
27. Liu X, Niu X, Zhou W, et al. The inhibition and mechanism of β-hydroxy acid isoamyl shikonin on the growth of prostate cancer cell lines [J]. J Shanghai Jiaotong Univ (Med Sci), 2010, 30: 527-530.
28. Rao Z, Liu X, Zhou W, et al. Synthesis and antitumor activity of β-hydroxyisovaleryl analogues [J]. Eur J Med Chem, 2011, 46: 3934-3941.
29. Liu J, Zhou W, Li SS, et al. Modulation of orphan nuclear receptor Nur77-mediated apoptotic pathway by acetylshikonin and analogues [J]. Cancer Res, 2008, 68: 8871-8880.
30. Hanif S, Shamim U, Ullah MF, et al. The anthocyanidin delphinidin mobilizes endogenous copper ions from human lymphocytes leading to oxidative degradation of cellular DNA [J]. Toxicology, 2008, 249: 19-25.
31. Lech T, Sadlik J. Copper concentration in body tissues and fluids in normal subjects of southern Poland [J]. Biol Trace Elem Res, 2007, 118: 10-15. (Pubitemid 47509502)
32. Mao X, Yu CR, Li WH, et al. Induction of apoptosis by shikonin through a ROS/JNK-mediated process in Bcr/Abl-positive chronic myelogenous leukemia (CML) cells [J]. Cell Res, 2008, 18: 879-888.
33. Hsu PC, Huang YT, Tsai ML, et al. Induction of apoptosis by shikonin through coordinative modulation of the Bcl-2 family, p27, and p53, release of cytochrome c, and sequential activation of caspases in human colorectal carcinoma cells [J]. J Agric Food Chem, 2004, 52: 6330-6337.
34. Cheng HM, Qiu YK, Wu Z, et al. DNA damage induced by shikonin in the presence of Cu (II) ions: potential mechanism of its activity to apoptotic cell death [J]. J Asian Nat Prod Res, 2011, 13: 12-19.
35. Ruan M, Yan M, Yang WJ, et al. Role of NF-kappaB pathway in shikonin induced apoptosis in oral squamous cell carcinoma Tca-8113 cells [J]. Shanghai J Stomatol, 2010, 19: 66-71.
36. Han W, Li L, Qiu S, et al. Shikonin circumvents cancer drug resistance by induction of a necroptotic death [J]. Mol Cancer Ther, 2007, 6: 1641-1649. (Pubitemid 46954031)
37. Xuan YY, Hu X. Naturally-occurring shikonin analogues-A class of necroptotic inducers that circumvent cancer drug resistance [J]. Cancer Lett, 2009, 274: 233-242.
38. Min R, Zun Z, Min Y, et al. Shikonin inhibits tumor invasion via down-regulation of NF-κB-mediated MMP-9 expression in human ACC-M cells [J]. Oral Dis, 2011, 17: 362-369.
39. Mao YJ, Li HH, Li JF. Signal transduction by protein tyrosine kinases and antitumor agents [J]. Acta Pharm Sin, 2008, 43: 323-334.
40. Wang XH, Fu LW. Advances in studies on inhibitor of apoptosis proteins and cancer therapy [J]. Acta Pharm Sin, 2006, 41: 103-107.
41. Zhu XF, Liu ZC, Zeng YX. Signal transduction by tyrosine kinase receptors and oncotherapy [J]. Acta Pharm Sin, 2002, 37: 229-234.
42. Takai N, Ueda T, Nishida M, et al. β-Hydroxyisovaleryl-shikonin has a profound anti-growth activity in human endometrial and ovarian cancer cells [J]. Gynecol Oncol, 2008, 109: 107-114.
43. Lee HJ, Magesh V, Nam D, et al. Shikonin, acetylshikonin, and isobutyroylshikonin inhibit VEGF-induced angiogenesis and suppress tumor growth in lewis lung carcinoma-bearing mice [J]. J Pharm Soc Jpn, 2008, 128: 1681-1688.
44. Froelich-Ammon SJ, Osheroff N. Topoisomerase poisons: harnessing the dark side of enzyme mechanism [J]. J Biol Chem, 1995, 270: 21429-21432.
45. Ahn BZ, Baik KU, Kweon GR, et al. Acylshikonin analogs: synthesis and inhibition of DNA topoisomerase-I [J]. J Med Chem, 1995, 38: 1044-1047.
46. Fujii N, Yamashita Y, Arima Y, et al. Induction of topoisomerase II-mediated DNA cleavage by the plant naphthoquinones plumbagin and shikonin [J]. Antimicrob Agents Chemother, 1992, 36: 2589-2594.
47. Zhang YJ, Li JG, Liu F, et al. The inhibition of telomerase activity in the inhibition of human renal cancer cell growth [J]. Cancer Control, 2003, 10: 935-937.